This clinical trial is focused on studying a condition known as acute ischemic stroke, which occurs when a blood clot blocks a blood vessel in the brain, leading to reduced blood flow and potential brain damage. Specifically, the study is looking at strokes caused by a blockage in the basilar artery, a major artery at the base of the brain. The trial will compare two treatments: Tenecteplase and Alteplase. Both are medications that help dissolve blood clots, but they are used in different ways and timeframes. Tenecteplase is given within 24 hours of stroke symptoms, while Alteplase is administered within 4.5 hours.

The purpose of the study is to determine if Tenecteplase is more effective than Alteplase or standard care in helping patients recover better from a stroke. Participants in the study will receive either Tenecteplase or Alteplase, or they may receive standard care, which could include no medication. Some patients may also undergo a procedure called thrombectomy, which involves physically removing the clot from the blood vessel. The study will monitor patients for up to 90 days to assess their recovery and overall health outcomes.

Throughout the study, researchers will evaluate the patients’ recovery using a scale called the Modified Rankin Scale (mRS), which measures the level of disability or dependence in daily activities. The goal is to see if patients can return to their normal activities or have minimal disability after treatment. The study will also look at other factors, such as early improvement in stroke symptoms and any complications that may arise. The findings from this study could help improve treatment options for patients experiencing a stroke due to basilar artery blockage.